Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16152580 | 0.79 | ADORA2A (0.34) | ADORA2AADORA1 | |
| SCHEMBL18040224 | 0.79 | HTT (0.33) | ADORA2AADORA1 | |
| SCHEMBL21663187 | 0.79 | HTT (0.33) | ADORA2AADORA1 | |
| SCHEMBL2535001 | 0.79 | SMN1; SMN2 (0.32) | ADORA2AADORA1 | |
| SCHEMBL20589128 | 0.76 | CYP2A6 (0.35) | — | |
| SCHEMBL20589390 | 0.75 | PIK3CA (0.41) | — | |
| SCHEMBL20784793 | 0.75 | MAT2A (0.32) | — | |
| SCHEMBL14090720 | 0.75 | — | — | |
| SCHEMBL29994083 | 0.75 | MAT2A (0.32) | — | |
| SCHEMBL5849528 | 0.75 | SELE (0.40) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-112047948-B | Kras mutant inhibitors | 山东轩竹医药科技有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11028097-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LIMITED (GB) | 2021-06-08 | — | — | US | disclosed |
| US-11028097-B2 | Thienopyrimidine compounds | VERNALIS (R&D) LIMITED (GB) | 2021-06-08 | — | — | US | disclosed |
| CN-112047948-A | Kras mutant inhibitors | 山东轩竹医药科技有限公司 | 2020-12-08 | — | — | CN | disclosed |
| EP-2947084-B1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO (CN) | 2020-09-23 | — | — | EP | disclosed |
| EP-3675856-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200140455-A1 | Thienopyrimidine Compounds | VERNALIS DEVELOPMENT LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-9045491-B2 | Thienyl [3,2-D] pyrimidin-4-one compounds, preparation method, pharmaceutical compositions and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-06-02 | — | — | US | disclosed |
| US-9045491-B2 | Thienyl [3,2-D] pyrimidin-4-one compounds, preparation method, pharmaceutical compositions and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-06-02 | — | — | US | disclosed |
| US-20140323466-A1 | THIENYL [3,2-D] PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-30 | — | — | US | disclosed |
| US-20140323466-A1 | THIENYL [3,2-D] PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-30 | — | — | US | disclosed |
| EP-2786998-A1 | THIENYL [3, 2-D]PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-10-08 | — | — | EP | disclosed |
| WO-2014111037-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海昀怡健康管理咨询有限公司 (CN) | 2014-07-24 | — | — | WO | disclosed |
| US-20110118284-A1 | THIENOPYRIMIDINE COMPOUNDS | VERNALIS (R&D) LTD. (GB) | 2011-05-19 | — | — | US | disclosed |
| EP-2205607-A1 | THIENOPYRIMIDINE COMPOUNDS | Vernalis (R&D) Ltd. (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009037463-A1 | THIENOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037463-A1 | THIENOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885 |
| US-20110118284-A1 | THIENOPYRIMIDINE COMPOUNDS | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA1 12/4885 |
| US-11028097-B2 | Thienopyrimidine compounds | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA1 12/4885 |
| US-20140323466-A1 | THIENYL [3,2-D] PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | DPP4, DPP7, DPP3 | ADORA2A 1541/4885ADORA1 787/4885 |
| US-20200140455-A1 | Thienopyrimidine Compounds | ADORA2B, TBXA2R, ADORA2A | ADORA2A 3/4885ADORA1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.